Drug Pipeline Database & Screener

Over 2000 drug entries from about 500 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Drug pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst. 

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates. 

Financial data are delayed 15-25 minutes.

Showing 540 companies
Screener
Sort
Stage
Indication
Market Cap
Price
Short ratio
Relative Volume
Price to book
Company
Price
Change
No of Shares
Market Cap
Short Ratio
Updated
$91.53
+1.39  +1.54%
1.5 billion
$137.7 billion
4.23
11/16/2018
Tap to view 39 drugs
Drug Indication Stage News
ABT-494 - SELECT-MONOTHERAPY Rheumatoid arthritis Phase 3 Phase 3 data released December 20, 2017 - primary endpoint and key secondary endpoints met.
Risankizumab Ulcerative colitis Phase 3 Phase 3 trial to be initiated 1H 2018.
ABT-494 - SELECT-COMPARE Rheumatoid arthritis Phase 3 Phase 3 data released April 9, 2018. Primary and secondary endpoints met.
ABT-414 Recurrent glioblastoma (rGBM) Phase 1 Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-494 - SELECT-BEYOND Rheumatoid arthritis Phase 3 Phase 3 top-line released September 11, 2017. Endpoints met but with two patient deaths.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
ABBV-8E12 Progressive supranuclear palsy (PSP) Phase 2 Phase 2 initiation announced January 25, 2017.
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Approved Approval announced June 11, 2018.
Venetoclax Relapsed or refractory multiple myeloma Phase 3 Phase 3 trial initiated July 2016.
Venclexta First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial planned.
Venclexta Follicular lymphoma (FL) Phase 3 Phase 3 trial planned.
Risankizumab Crohn’s Disease Phase 3 Phase 3 trial to commence 2H 2017.
Risankizumab Psoriasis BLA Filing Phase 3 data released October 26, 2017 - primary endpoints met. BLA filing announced April 25, 2018.
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commenced 2017.
ABT-494 (upadacitinib) - SELECT-NEXT Rheumatoid arthritis Phase 3 Phase 3 top-line data released June 7, 2017 - primary endpoints met.
Risankizumab Psoriatic Arthritis Phase 2b Phase 3 trial planned for 2018.
ABT-494 Crohn’s Disease Phase 3 Phase 3 trial initiated late 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
ABT-494 Atopic Dermatitis Phase 3 Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
Elagolix Uterine Fibroids Phase 3 Phase 3 data released February 21, 2018 - primary endpoint met. Second Phase 3 trial also met primary endpoint - March 13, 2018.
Elagolix Endometriosis Approved FDA approval announced July 24, 2018.
ABT-494 - SELECT-EARLY Rheumatoid arthritis Phase 3 Phase 3 trial met all endpoints - June 5, 2018. Regulatory filing due 2H 2018.
Rova-T (TAHOE) Second-line Small Cell Lung Cancer Phase 3 Phase 3 data due 2020.
Rova-T (MERU) First-line Small Cell Lung Cancer Phase 3 Phase 3 data due 2020.
Imbruvica and Gazyva - iLLUMINATE Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) PDUFA priority review sNDA accepted for priority review - noted October 17, 2018. PDUFA date not given. Estimate 1Q 2019.
IMBRUVICA (ibrutinib) Waldenström’s Macroglobulinemia Approved FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib) Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta First line unfit AML PDUFA priority review PDUFA date December 25, 2018.
Upadacitinib - U-ACHIEVE Ulcerative colitis Phase 2/3 Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Venetoclax Chronic Lymphocytic Leukemia Phase 3 Phase 3 data released October 31, 2018 - PFS primary endpoint met.
$8.25
+0.2  +2.48%
47.9 million
$395.5 million
11/16/2018
Tap to view 4 drugs
Drug Indication Stage News
ABO-101 Sanfilippo syndrome type B (MPS IIIB) Phase 1/2 Phase 1/2 commencement of enrollment announced December 20, 2017.
EB-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 1/2 Phase 1/2 poster due at Society for Investigative Dermatology (SID) April 28, 2017. Noted January 29, 2018 intention to commence Phase 3 trial in 2018.
ABO-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 2 Phase 2 enrollment commenced September 2016.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 updated data released February 8, 2018. CSF heparan sulfate levels decreased 57%/64%.
$0.56
+0.02  +3.70%
13.9 million
$7.8 million
11/16/2018
Tap to view 1 drug
ABLX Ablynx NV
$0.00
  +0.00%
78 million
$
11/01/2018
Tap to view 5 drugs
Drug Indication Stage News
ALX-0171 Respiratory syncytial virus (RSV) Phase 2 Phase 2 trial initiation announced April 29, 2018. Data due 2H 2018.
Caplacizumab Acquired thrombotic thrombocytopenic purpura (aTTP) Phase 3 BLA filing due 1H 2018.
Vobarilizumab Rheumatoid Arthritis Phase 2b Phase 2b completed. Awating opt-in decision from Abbvie expected 2018.
Vobarilizumab Systemic lupus erythematosus (SLE) Phase 2 Phase 2 trial did not meet primary endpoint - March 26, 2018.
ALX-0171 Infants Hospitalized for Respiratory Syncytial Virus Phase 2b Phase 2b data due 2H 2018.
$4.71
+0.13  +2.84%
55.5 million
$261.3 million
11/16/2018
Tap to view 5 drugs
Drug Indication Stage News
ARB-1467, tenofovir, and pegylated interferon Hepatitis B (HBV) Phase 2 Phase 2 trial ongoing but no plans to continue further development.
AB-423 (MAD) Hepatitis B (HBV) Phase 2 Phase 2 trial to be initiated 1Q 2018.
ARB-1467 Hepatitis B (HBV) Phase 2 Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
AB-452 Hepatitis B Phase 1 Phase 1 trial initiation delayed - noted October 9, 2018.
AB-506 Hepatitis B (HBV) Phase 1 Phase 1 trial to be completed 2Q 2019.
$18.93
+0.3  +1.61%
125.1 million
$2.4 billion
11/16/2018
Tap to view 6 drugs
Drug Indication Stage News
Pimavanserin - CLARITY Adjunctive Treatment in Patients With Major Depressive Disorder Phase 2 Phase 2 data released October 31, 2018 - noted overall primary endpoint met BUT did not benefit placebo in re-randomized stage.
Pimavanserin - Advance Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 2 Phase 2 initiated November 2016. Data due 2019.
Pimavanserin - Enhance Adjunctive treatment of schizophrenia Phase 3 Phase 3 initiated November 2016. Data due 2019.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Announced October 4, 2017 that trial will be discontinued.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - Harmony Alzheimer’s disease psychosis Phase 3 Phase 3 trial initiation announced October 4, 2017.
$25.58
+1.4  +5.79%
10.1 million
$257.2 million
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
EDSIVO Vascular Ehlers-Danlos Syndrome NDA Filing NDA filing announced October 29, 2018.
Tovaxin (Tcelna) Secondary Progressive MS (SPMS) Phase 2b Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001 Urea cycle disorder (UCD) Phase 2 NDA filing planned for 2019.
$2.88
+0.16  +5.88%
138.6 million
$399.2 million
11/16/2018
Tap to view 7 drugs
Drug Indication Stage News
ACH-4471 C3 glomerulopathy (C3G) Phase 2 Phase 2 interim data due December 17, 2018.
JNJ-4178 Hepatitis C (HCV) Phase 2a Janssen noted September 11, 2017 that no further development planned.
ACH-4471 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 interim data due December 17, 2018.
JNJ-4178 - OMEGA-1 Hepatitis C (HCV) Phase 2b Janssen noted September 11, 2017 that no further development planned.
ACH-4471 C3 glomerulopathy (C3G) Phase 2 Phase 2 longer duration data due 2H 2018.
ACH-5228 Healthy volunteers Phase 1 Phase 1 interim data due December 17, 2018.
ACH-5548 Healthy volunteers Phase 1 Phase 1 interim data due December 17, 2018.
$1.79
-0.03  -1.65%
6.7 million
$12 million
11/16/2018
Tap to view 1 drug
Drug Indication Stage News
Cytisine Smoking cessation Phase 2b Phase 2b trial initiation announced October 30, 2018 with data due mid-2019.
$9.77
+0.12  +1.24%
67.4 million
$658.1 million
11/16/2018
Tap to view 6 drugs
$8.81
+0.13  +1.50%
40.9 million
$360.6 million
11/16/2018
Tap to view 9 drugs
Drug Indication Stage News
ATI-502 (AA-201 Topical) - dose ranging Alopecia areata Phase 2 Phase 2 data due 1H 2019.
ATI-502 (VITI-201 Topical) Vitiligo Phase 2 Phase 2 open label data due 1H 2019.
ATI-502 AUATB-201 - open label Alopecia areata - regrowth of eyebrows Phase 2 Phase 2 trial ongoing.
ATI-501 (AUAT-201 Oral) Alopecia areata Phase 2 Phase 2 data due 2H 2019.
ESKATA (hydrogen peroxide) Seborrheic keratosis (SK) Approved Approval announced December 15, 2017.
A-101 THWART-1 and THWART-2 Common warts (verruca vulgaris) Phase 3 Phase 3 data due 2H 2019.
ATI-502 AA-202 Topical - PK/safety Alopecia areata Phase 2 Phase 2 interim data released June 28, 2018.
ATI-502 - open label Androgenetic alopecia (AGA) - Hair loss Phase 2 Phase 2 data due 1H 2019.
ATI-502 Atopic dermatitis (AD) Phase 2 Phase 2 data due mid-2019.
$2.93
+0.09  +3.17%
61.9 million
$181.4 million
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (ARX-04) Moderate-to-severe acute pain following a surgical procedure Approved FDA Approval announced November 2, 2018.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. Additional clinical trial required. Data released August 1, 2017. NDA resubmission due 2H 2018.
$0.73
-0.02  -2.67%
78.1 million
$57 million
11/16/2018
Tap to view 1 drug
Drug Indication Stage News
CaPre (TRILOGY trial) Hypertriglyceridemia Phase 3 Phase 3 top-line data due by the end of 2019.
$5.43
-0.07  -1.27%
104.6 million
$567.8 million
11/16/2018
Tap to view 8 drugs
Drug Indication Stage News
NY-ESO T-cell therapy Synovial sarcoma - cancer Phase 1/2 Oral presentation at CTOS November 9, 2017.
NY-ESO T-cell therapy Ovarian cancer Phase 1/2 Reported no clinical responses October 2016. Intends to alter dosage to include fludarabine.
NY-ESO T-cell therapy Myxoid round cell liposarcoma (MRCLS) Phase 1/2 Phase 1/2 presentation at SITC November 2018.
NY-ESO T-cell therapy Myeloma Phase 1/2 Updated data at ASH December 2017 - Overall response rate (ORR) at 100 days and one year were 76% and 44%.
NY-ESO T-cell therapy Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 initiated November 2015. Data are due 2017.
MAGE-A4 Soild tumors Phase 1 Phase 1 data at ESMO noted best response was 4/6 with stable disease.
AFP Hepatocellular carcinoma Phase 1 Initial safety data due late 2018.
MAGE-A10 Non-Small Cell Lung Cancer (NSCLC) Phase 1 Phase 1 data at ESMO noted no current response.
$1.44
+0.06  +4.06%
6.5 million
$9.4 million
11/16/2018
Tap to view 1 drug
Drug Indication Stage News
AD04 Alcohol use disorder Phase 3 Phase 3 European trial planned. US trials not planned.
$5.15
+0.12  +2.39%
46.3 million
$238.7 million
11/16/2018
Tap to view 2 drugs
Drug Indication Stage News
RI-002 Primary Immune Deficiency Diseases PDUFA CRL issued July 29 2016. New PDUFA date April 2, 2019.
BIVIGAM Primary humoral immunodeficiency PDUFA PDUFA date delayed two months to December 18, 2018.
$2.60
-0.18  -6.47%
47.3 million
$123 million
11/16/2018
Tap to view 5 drugs
Drug Indication Stage News
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000 Asthma/COPD Phase 2 Phase 3 planned for December 2018.
Symjepi - low dose Anaphylaxis Approved FDA Approval announced September 27, 2018.
APC-6000 Opioid overdose NDA Filing NDA filing due YE 2018.
APC-8000 (sublingual tadalafil) NDA Filing NDA filing due 4Q 2018.
$10.82
-0.02  -0.18%
27.3 million
$295.8 million
11/16/2018
Tap to view 5 drugs
Drug Indication Stage News
ADS-4101 Partial onset seizures in patents with epilepsy Phase 1b Phase 1b top-line data released September 7, 2017. Pivotal Phase 3 trial to be initiated 2019.
GOCOVRI (amantadine) Multiple sclerosis (MS) Phase 3 Phase 3 commencement of enrollment announced April 3, 2018. Enrollment to be completed 2H 2019.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
ADS-5102 Levodopa-Induced Dyskinesia Approved Approval announced August 24, 2017.
GOCOVRI (amantadine) Dyskinesia patients with Parkinson's disease Phase 3 Phase 3 open-label data released April 19, 2018.
$3.28
-0.01  -0.30%
79.4 million
$260.4 million
11/16/2018
Tap to view 9 drugs
Drug Indication Stage News
BION-1301 Multiple Myeloma Phase 1/2 Phase 1/2 initiation announced December 18, 2017.
ADU-S100 Solid tumors or lymphomas Phase 1b Initial data due at SITC November 2018 noted 2/40 PRs and 11 with SD.
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial Pancreatic cancer Phase 2b Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with pembrolizumab Mesothelioma - cancer Phase 2 Noted December 12, 2017 that development to be discontinued.
ADU-S100 and PDR001 Solid tumors or lymphomas Phase 1b Initial data due 2H 2018.
pLADD Colorectal Cancer Phase 1 Phase 1 additional additional immunological data due by end of 2018.
pLADD Colorectal Cancer Phase 1 Phase 1 additional additional immunological data due by end of 2018.
ADU-214 with Nivolumab Non-Small Cell Lung Cancer Phase 1/2 Phase 1b initiation announced June 7, 2018.
$3.82
+0.09  +2.41%
62.9 million
$240.2 million
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
ADVM-043 Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/2 Development to be discontinued - noted November 1, 2018.
AVA-101 Wet age-related macular degeneration (Wet-AMD) Phase 2a Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
ADVM-022 Wet age-related macular degeneration (Wet-AMD) Phase 1 Phase 1 trial to be initiated 4Q 2018.
$0.50
+0.05  +10.87%
69.5 million
$34.5 million
11/16/2018
Tap to view 7 drugs
Drug Indication Stage News
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Enrollment to be terminated - noted November 2, 2018.
ADXS-PSA and Keytruda - KEYNOTE-046 Castrate-resistant prostate cancer Phase 1/2 Updated data due 1Q 2019.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Announced Phase 3 first patient dosed - February 6, 2017. Noted November 2, 2018 intention to continue trial.
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
ADXS-NEO Non-small cell lung cancer (NSCLC) Phase 1 Phase 1 tolerability data due 1H 2019.
ADXS-503 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 trial to be initiated by the end of 2018.
$42.87
+0.14  +0.33%
45.5 million
$1.9 billion
11/16/2018
Tap to view 2 drugs
Drug Indication Stage News
Roclatan Glaucoma PDUFA PDUFA date March 14, 2019.
Rhopressa Glaucoma Approved PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
$2.90
+0.36  +14.17%
16.4 million
$47.7 million
11/16/2018
Tap to view 2 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Approved CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
$4.26
+0.13  +3.15%
62.4 million
$265.9 million
11/16/2018
Tap to view 4 drugs
Drug Indication Stage News
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b updated data due at ASH December 1, 2018 6:15 PM.
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a ongoing.
AFM13 CD30-positive lymphoma Phase 1/2 Phase 1b/2a updated data due at ASH December 2, 2018 6:00 PM.
AFM11 Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) Phase 1 Phase 1 trial placed on clinical hold - October 8, 2018.
$2.11
-0.08  -3.65%
120 million
$253.2 million
11/16/2018
Tap to view 7 drugs
Drug Indication Stage News
AGEN2034 and AGEN1884 Solid tumors Phase 1/2 Phase 1/2 data presented at ESMO October 2018 noted clinical benefit in 7/16 patients.
AGEN1884 (anti-CTLA-4) Solid cancers Phase 1 Phase 1 presentation at ASCO 2018. 31% ORR.
Shingrix Shingles Approved Approval announced October 20, 2017.
AGEN2034 (anti-PD-1) Cervical cancer Phase 1/2 Phase 1 data presented at ESMO October 2018 noted clinical benefit of 3/7 cervical cancer patients.
INCAGN1949 Solid tumors - cancer Phase 1/2 Phase 1/2 trial initiation announced November 30, 2016.
INCAGN1876 Solid tumors - cancer Phase 1/2 Phase 1/2 trial commenced June 2016
AGEN 1884 plus Keytruda Non-small cell lung cancer (NSCLC) Phase 2 Phase 2 data due 2018.
$69.64
+2.37  +3.52%
58.2 million
$4.1 billion
11/16/2018
Tap to view 13 drugs
Drug Indication Stage News
AG-348 Thalassemia Phase 2 Phase 2 trial to be initiated 4Q 2018.
Ivosidenib IDH1m Relapsed/Refractory AML - cancer Approved FDA Approval announced July 20, 2018.
AG-348 Pyruvate kinase deficiency Phase 3 Phase 3 trial initiation announced June 18, 2018.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 initiated 2Q 2017.
Enasidenib (AG-221) - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
AG-120 Ivosidenib IDH1 mutant positive cholangiocarcinoma - cancer Phase 3 Phase 3 initiated December 2016. Enrollment to be completed 1H 2019.
AG-120 Ivosidenib R/R Acute Myeloid Leukemia (AML) Phase 1 Phase 1 data at ASCO June 2018 noted CR rate was 24%.
Enasidenib or ivosidenib with VIDAZA Frontline AML with IDH1 or IDH2 mutation Phase 1/2 Phase 1/2 updated data at ASCO June 2018. ORR of 78%, CR Rate of 44%.
Ivosidenib or enasidenib Frontline AML with IDH1 or IDH2 mutation Phase 1 Phase 1 updated data at ASH December 3, 2018 at 7:15 a.m. PST. Phase 3 trial to be initiated 4Q 2018.
AG-270 Solid tumors Phase 1 Phase 1 dosing of first patient announced March 19, 2018.
AG-881 Glioma Phase 1 Phase 1 data presented at ASCO June 1, 2018. 1 minor response + 1 partial response out of 93 patients.
Ivosidenib Acute Myeloid Leukemia (AML) Phase 1 Phase 1 data to be presented at ASH December 3, 2018 at 7:30 a.m. PST.
$8.31
+0.24  +2.97%
22 million
$182.8 million
11/16/2018
Tap to view 7 drugs
Drug Indication Stage News
AEB1102 + KEYTRUDA Small cell lung cancer (SCLC) Phase 1/2 Phase 1/2 top-line safety and clinical data due 4Q 2018.
AEB1102 Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS) Phase 1 Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
Pegzilarginase (AEB1102) Arginase I deficiency Phase 1/2 Phase 2 interim data presented October 17, 2018. Pivotal trial to be initiated 2019.
AEB1102 Solid tumors Phase 1 Phase 1 dose escalation data presented at AACR April 15, 2018.
Pegzilarginase (AEB1102) Solid tumors Phase 1 Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102) + KEYTRUDA Small cell lung cancer (SCLC) Phase 1/2 Phase 1/2 top-line safety and clinical data due 4Q 2018.
AEB1102 Solid tumors Phase 1 Monotherapy data due 4Q 2018.
$157.39
-1.98  -1.24%
337.3 million
$53.1 billion
1.23
11/16/2018
Tap to view 27 drugs
Drug Indication Stage News
Botox Forehead lines Approved Approval (third indication) announced October 3, 2017.
ABP 980 Herceptin biosimilar BLA Filing BLA filing announced July 31, 2017.
RTGel in combination with BOTOX Overactive Bladder (OAB) Phase 2 Phase 2 data due 2019.
JUVÉDERM VOLLURE Correction of moderate to severe facial wrinkles and folds Approved Approval announced March 20, 2017.
Brazikumab Crohn's disease Phase 3 Phase 3 to be initiated 2H 2018 with data due 2020.
Bimatoprost Androgenic Alopecia Phase 3 Phase 3 enrollment to be completed 2H 2018.
Botox Depression Phase 2 Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Cariprazine Bipolar I depression Phase 3 Phase 3 data released December 18, 2017 - primary endpoint met.
RORγt agonist Psoriasis Phase 2b Phase 2b trial ongoing.
Cariprazine Maintenance Treatment of Schizophrenia Approved Approval announced November 13, 2017.
ATOGEPANT Prophylaxis (migraine) Phase 2b Phase 3 trial to be initiated 1H 2019.
RAPASTINEL Major depressive disorder (MDD) Phase 3 Phase 3 initiated October 2016. Data due 1H 2019.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 initiated 2H 2017 with top-line data due 2020.
ESMYA (ulipristal acetate) Uterine Fibroids CRL CRL issued August 21, 2018.
ABICIPAR Diabetic macular edema (DME) Phase 3 Phase 3 trial to be initiated 2019.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 trial has been initiated.
ABICIPAR Age-related macular degeneration (AMD) Phase 3 Phase 3 data released July 19, 2018. Primary endpoint met. BLA filing due 1H 2019.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) Approved sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults Chronic idiopathic constipation (CIC) Approved sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Sarecycline Severe acne vulgaris Approved FDA Approval announced October 2, 2018.
Cariprazine Bipolar I Depression Phase 3 Phase 3 data released April 3, 2018. Primary endpoint met. sNDA filing due 2H 2018.
UBROGEPANT Migraine Phase 3 NDA filing due 1Q 2019.
Brazikumab Ulcerative colitis Phase 2 Phase 2 trial to be initiated 2H 2018.
Brimo DDS Geographic atrophy Phase 3 Phase 3 trial to be initiated 2H 2018.
Bimatoprost Open-angle glaucoma or ocular hypertension Phase 3 Phase 3 safety data due 1H 2019.
$0.86
+0.01  +1.36%
34.4 million
$29.4 million
11/16/2018
Tap to view 1 drug
$6.86
-0.04  -0.58%
18.1 million
$124.4 million
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
AAV Gene Therapy CNGB3 Achromatopsia Phase 1/2 Phase 1/2 dose escalation part of trial to be completed 1Q 2019.
rAAV-hRS1 X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 interim data due by the end of December 2018.
AAV-based gene therapy X-linked Retinitis Pigmentosa (XLRP) Phase 1/2 Phase 1/2 dose escalation part of trial to be completed 1Q 2019.
$29.62
+0.04  +0.14%
58.7 million
$1.7 billion
11/16/2018
Tap to view 6 drugs
Drug Indication Stage News
AR101 ARTEMIS Peanut Allergy Phase 3 Phase 3 enrollment has commenced - noted June 5, 2017. Data due 1H 2019.
AR101 RAMSES Peanut Allergy Phase 3 Phase 3 data released November 8, 2018 noted no serious adverse events
AR101 PALISADE Peanut Allergy Phase 3 Phase 3 data released February 20, 2018 met primary endpoint. BLA filing due 2018.
AR 201 Egg Allergy Phase 2 Phase 2 trial to be initiated 1H 2019.
AR 301 Walnut Allergy Phase 2 Phase 2 trial to be initiated 2H 2019.
AR101 with adjunctive dupilumab Peanut Allergy Phase 2 Phase 2 trial initiation announced October 15, 2018.
$1.64
-0.14  -7.61%
46.1 million
$75.6 million
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
C-Scape Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens Phase 3 Phase 3 trial delayed due to decision to run a further Phase 1 trial first - noted May 4, 2018.
Plazomicin Complicated urinary tract infections (cUTI) Approved FDA approval for cUTI but CRL received for the treatment of bloodstream infection (BSI).
Plazomicin - CARE Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE) Phase 3 Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
$7.97
+0.05  +0.63%
57.1 million
$454.8 million
11/16/2018
Tap to view 4 drugs
Drug Indication Stage News
Vadadustat - TRILO2GY Three-times-weekly dosing regimen for vadadustat Phase 3 Phase 3 trial to be initiated in late 2018 or early 2019, with top-line results expected in early 2020.
Vadadustat - FO2RWARD Renal anemia Phase 2 Phase 2 trial data due 1H 2019.
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 data due 1Q 2020.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 data due mid-2020.
$29.98
+1.81  +6.43%
89.2 million
$2.7 billion
11/16/2018
Tap to view 8 drugs
Drug Indication Stage News
AKCEA-ANGPTL3-LRx Rare hyperlipidemias Phase 2 Phase 2 top-line data due 2019.
AKCEA-ANGPTL3-LRx Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus Phase 2 Phase 2 top-line data due 2019.
AKCEA-APOCIII-LRx Hyperlipoproteinemia and established cardiovascular disease Phase 2b Phase 2b trial initiation announced January 5, 2017. Top-line data due 2019.
AKCEA-APO(a)-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 2b Phase 2 data presented at AHA November 2018 - endpoints met.
Inotersen (IONIS-TTRRx) NEURO-TTR - familial amyloid polyneuropathy (FAP). Approved FDA Approval announced October 5, 2018,
Volanesorsen - APPROACH Familial chylomicronemia syndrome (FCS) CRL CRL issued August 27, 2018.
Volanesorsen Partial lipodystrophy rapidly Phase 3 Phase 3 initiated November 2015
Volanesorsen Familial partial lipodystrophy (FPL) Phase 3 Phase 3 data due 2019.
$1.75
+0.04  +2.28%
15.3 million
$26.7 million
11/16/2018
Tap to view 4 drugs
Drug Indication Stage News
Coversin Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 interim data released April 24, 2017. Further update December 8, 2017 noted that primary endpoint was met. Phase 3 program to commence late 1Q 2018.
Coversin Atopic keratoconjunctivitis Phase 1/2 Phase 1/2 data due 1Q 2019.
Coversin Bullous Pemphigoid Phase 2 Phase 2 data due 1Q 2019.
Coversin Atypical hemolytic-uremic syndrome (aHUS) Phase 1 Phase 2 trial initiated late 2017.
$26.44
+0.76  +2.96%
12 million
$316.5 million
11/16/2018
Tap to view 1 drug
Drug Indication Stage News
A4250 - PEDFIC- 1 Liver disease Phase 3 Phase 3 top-line data due late 2019 or early 2020.
$8.81
+0.04  +0.46%
26.2 million
$231.2 million
11/16/2018
Tap to view 5 drugs
Drug Indication Stage News
ADX-102 Dry eye syndrome Phase 2b Phase 3 planned for 2019.
Reproxalap (ADX-102) Allergic conjunctivitis Phase 3 Phase 3 data due early 2019.
ADX-102 Noninfectious anterior uveitis Phase 3 Phase 3 data due 2H 2019.
ADX-102 Sjögren-Larsson Syndrome (SLS) Phase 3 Phase 3 initial data due in 2019.
ADX-1612 (ganetespib) Mesothelioma Phase 2 Phase 2 trial to be initiated in 2019.
$1.01
+0.01  +1.00%
70.1 million
$70.8 million
11/16/2018
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$34.49
+0.4  +1.17%
155.4 million
$5.4 billion
11/16/2018
Tap to view 10 drugs
Drug Indication Stage News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) Schizophrenia Approved FDA approval announced July 2, 2018.
ALKS 3831 - ENLIGHTEN-Early Schizophrenia - young adults Phase 3 Phase 3 initiation announced June 8, 2017.
ALKS 3831 - ENLIGHTEN-2 Schizophrenia Phase 3 Phase 3 data due 4Q 2018.
BYDUREON Type 2 diabetes Approved CRL received March 15, 2010.
Aristada Schizophrenia Approved Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
ALKS 8700 (BIIB098) Multiple sclerosis (MS) Phase 3 NDA filing due 4Q 2018.
ALKS 6428 Opioid dependence Phase 3 Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 5461 Major depressive disorder PDUFA PDUFA date of January 31, 2019. Advisory Committee Meeting November 1, 2018 voted 2-21 against recommending approval.
ALKS 3831 - ENLIGHTEN-1 Schizophrenia Phase 3 Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230 Solid tumors Phase 1 Phase 1 initial data at SITC November 9, 2018.
$58.99
+3.07  +5.49%
42.1 million
$2.5 billion
11/16/2018
Tap to view 4 drugs
Drug Indication Stage News
AK002 Severe Allergic Conjunctivitis Phase 1 Phase 1 data due 1Q 2019.
AK002 Indolent Systemic Mastocytosis Phase 1 Phase 1 data due 1Q 2019.
AK002 Chronic Urticaria Phase 2 Phase 2 data due 1Q 2019.
AK002 Eosinophilic Gastritis Phase 2 Phase 2 top-line data due mid-2019.
$27.98
+1.05  +3.90%
$
11/16/2018
Tap to view 2 drugs
Drug Indication Stage News
UCART19 (PALL) Acute lymphoblastic leukemia (ALL) Phase 1 Phase 1 update at ASH December 3, 2018, 4:30pm.
UCART19 - CALM Refractory B-cell Acute Lymphoblastic Leukaemia Phase 1 Phase 1 interim data update likely late 2018.
$8.61
+0.07  +0.82%
20.8 million
$178.8 million
11/16/2018
Tap to view 2 drugs
Drug Indication Stage News
Reloxaliase ALLN-177 (URIROX-1) Enteric Hyperoxaluria Phase 3 Data from first Phase 3 trial due 2H 2019.
Reloxaliase ALLN-177 Primary hyperoxaluria Phase 2 Phase 2 interim data due 1H 2019 and top-line data due 2H 2019.
$73.16
+3.79  +5.46%
101 million
$7.4 billion
11/16/2018
Tap to view 13 drugs
Drug Indication Stage News
ALN-CC5 (cemdisiran) Atypical hemolytic-uremic syndrome (aHUS) Phase 1/2 Phase 2 trial initiation announced September 26, 2017 with initial data due 2018.
Fitusiran Hemophilia A and B Phase 2 Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Givosiran Acute hepatic porphyrias Phase 3 Phase 3 positive interim analysis reported September 27, 2018. Full data due early 2019 with rolling NDA to commence 4Q 2018.
Inclisiran - ORION-9 Hypercholesterolemia Phase 3 Phase 3 completion of enrollment announced February 20, 2018 enrollment to be completed 1H 2018. Data 3Q 2019.
ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Ongoing as of February 2017.
Lumasiran (ALN-GO1) Primary Hyperoxaluria Type 1 (PH1) Phase 3 Phase 3 data due late-2019.
Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Approved FDA Approval announced August 10, 2018.
Revusiran ENDEAVOUR ATTR in patients with familial amyloidotic cardiomyopathy (FAC) Phase 3 Phase 3 trial discontinued October 2016.
ALN-CC5 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Phase 1/2 initial data presented at ASH 2016.
Fitusiran (ATLAS) Hemophilia Phase 3 Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Phase 3 first read-out expected 2H 2019
ALN-TTRsc02 - HELIOS-A ATTR amyloidosis Phase 3 Phase 3 trial to be initiated late 2018.
Inclisiran - ORION-10 Cardiovascular disease (ASCVD) Phase 3 Phase 3 enrollment target met - noted March 9, 2018. Data due 3Q 2019.
Inclisiran - ORION 11 Cardiovascular disease (ASCVD) Phase 3 Phase 3 target enrollment met - noted January 25, 2018. Data due 3Q 2019.
$5.26
+0.12  +2.36%
13.9 million
$72.9 million
11/16/2018
Tap to view 1 drug
Drug Indication Stage News
N91115 Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein Phase 2 Phase 2 data released February 24, 2017 - primary endpoint not met.
$2.17
-0.08  -3.56%
14.7 million
$32 million
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
ALRN-6924 Peripheral T-cell lymphoma (PTCL) Phase 2a Phase 2a interim data due at ASH December 1, 2018: 6:15 PM.
ALRN-6924 Solid tumors - cancer Phase 1/2 Phase 1 initial data presented at ASCO 2017. Completion of enrollment January 2017.
ALRN-6924 Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS) Phase 1b Phase 1/1b interim data due at ASH December 3, 2018: 6:00 PM.
$3.20
-0.08  -2.44%
8.8 million
$28 million
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
HepTCell Hepatitis B Phase 1 Phase 1 data due 4Q 2018.
NasoVAX Flu vaccine Phase 2 Phase 2 additional data released September 4, 2018.
NASOSHIELD Anthrax Phase 1 Phase 1 data due 4Q 2018.
$118.62
-1.06  -0.89%
223.1 million
$26.5 billion
11/16/2018
Tap to view 5 drugs
Drug Indication Stage News
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Phase 3 primary endpoint met - September 24, 2018.
ALXN1210 atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 data due early 2019.
ALXN1210 Paroxysmal nocturnal hemoglobinuria (PNH) PDUFA priority review PDUFA date under priority review February 18, 2019. Presentation at ASH December 3, 2018, 11:00am PT.
Eculizumab Refractory generalized myasthenia gravis (gMG) Approved Approval announced October 23, 2017.
WTX101 Wilson disease Phase 3 Phase 3 trial is enrolling.
$17.99
-0.01  -0.06%
34.5 million
$621.3 million
11/16/2018
Tap to view 5 drugs
Drug Indication Stage News
Digoxin immune fab (DIF) Severe preeclampsia in pregnant women Phase 2/3 Phase 2/3 commencement of enrollment announced June 1, 2017.
Rekynda Hypoactive sexual desire disorder (HSDD) Phase 3 NDA filing due early 2018.
Rekynda (Bremelanotide) Female sexual dysfunction (FSD) PDUFA PDUFA date March 23, 2019 but noted November 13, 2018 that a 3-6 month delay is likely due to FDA request for further data.
Feraheme Adults with iron deficiency anemia (IDA) Approved Approval for sNDA filing announced February 5, 2018.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy Approved Approval announced February 14, 2018.
AMGN Amgen Inc.
$194.18
+1.73  +0.90%
637.2 million
$123.7 billion
11/16/2018
Tap to view 21 drugs
Drug Indication Stage News
Tezepelumab - NAVIGATOR Asthma Phase 3 Phase 3 data due 2020.
Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP) Approved Approval announced May 21, 2018.
KYPROLIS (ASPIRE) Relapsed Multiple Myeloma Approved sNDA approval announced June 11, 2018.
Vectibix (Panitumumab) Wild-Type RAS Metastatic Colorectal Cancer Approved sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) PDUFA Approved September 14, 2017.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine Approved Approval announced May 17, 2018.
CNP 520 Alzheimer’s Disease Phase 3 Phase 3 ongoing. Expected completion 2024.
Repatha Cardiovascular disease Approved Approval announced December 1, 2017.
XGEVA Multiple Myeloma Approved sBLA approval announced January 5, 2017.
KYPROLIS (ARROW) Multiple Myeloma Approved FDA approval announced October 1, 2018.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma Approved sNDA approved January 17, 2018.
BLINCYTO Ph+ R/R ALL Approved PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma Phase 3 Phase 3 enrolling.
ABP 980 Herceptin biosimilar BLA Filing BLA filing announced July 31, 2017.
ABP 710 REMICADE biosimilar - rheumatoid arthritis Phase 3 Phase 3 data likely due 2H 2018.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
EVENITY (Romosozumab) Osteoporosis BLA Filing CRL issued July 16, 2017. BLA resubmission announced July 13, 2018.
AMG 301 Migraine Phase 2 Phase 2 data due by end of 2018.
AMG 420 Relapsed. Refractory (R/R) Multiple Myeloma (MM) Phase 1 Phase 1 data at ASH December 3, 2018 6:30 p.m. PT
AMG 330 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Phase 1 Phase 1 data at ASH December 1, 2018 7:30 a.m.
$0.58
+0.01  +1.44%
106.7 million
$61.6 million
11.39
11/16/2018
Tap to view 2 drugs
Drug Indication Stage News
Ampion Osteoarthritis of the Knee Phase 3 Noted August 7, 2018 that further trials required before filing BLA.
Optina Diabetic Macula Edema Phase 2b Phase 2b data released May 2015 did not meet endpoints
$20.67
-0.25  -1.20%
46.1 million
$952.9 million
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
Albuterol DPI Asthma Phase 2b
Naloxone Intranasal Opioid overdose CRL CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
$18.15
+0.43  +2.43%
315.2 million
$5.7 billion
11/16/2018
Tap to view 1 drug
Drug Indication Stage News
Vascepa REDUCE-IT outcomes trial High Triglycerides With Mixed Dyslipidemia Phase 3 Data presented at AHA November 10, 2018 noted 26% decrease in risk of death/heart attack.
$18.51
+0.01  +0.05%
298.6 million
$5.5 billion
6.47
11/16/2018
Tap to view 1 drug
Drug Indication Stage News
IPX203 Parkinson's disease Phase 3 Phase 3 initiation announced May 7, 2018.
$68.58
+4.09  +6.34%
26.8 million
$1.8 billion
11/16/2018
Tap to view 5 drugs
Drug Indication Stage News
ANB020 Moderate-to-severe adult atopic dermatitis Phase 2b Phase 2b data due 2H 2019.
ANB020 Severe adult eosinophilic asthma Phase 2a Phase 2a data released September 24, 2018. Full data due 2019 with Phase 2b trial to be initiated also in 2019.
ANB019 Palmo-plantar pustular psoriasis Phase 2 Phase 2 data due 2H 2019.
ANB019 Generalized pustular psoriasis Phase 2 Phase 2 data due mid-2019.
ANB020 Nasal polyps Phase 2 Phase 2 data due 2H 2019.
$35.71
+0.8  +2.29%
14.2 million
$507.5 million
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Phase 3 trial did not meet primary endpoint - June 19, 2018.
Monovisc Osteoarthritis Approved Approved Feb 2014
HYALOFAST Cartilage defects of the knee Phase 3 Phase 3 enrollment to be completed by the end of 2018.
$4.01
+0.2  +5.25%
18.7 million
$75 million
11/16/2018
Drug Indication Stage News
$0.06
-0.01  -12.86%
26.2 million
$1.6 million
2.04
11/16/2018
Tap to view 4 drugs
Drug Indication Stage News
Sollpura - RESULT Exocrine pancreatic insufficiency Phase 3 Phase 3 data released March 12, 2018 did not meet primary endpoint.
Blisibimod IgA nephropathy Phase 2 Phase 2 primary endpoint not met following interim analysis. Trial to continue. Top-line data released August 28, 2017.
Sollpura (liprotamase) Cystic fibrosis who suffer from exocrine pancreatic insufficiency Phase 3 Top-line data released December 27, 2016 - missed primary endpoint.
Blisibimod Lupus Phase 3 Phase 3 trial did not meet endpoints - November 10, 2016.
$0.25
-0.01  -2.00%
32.3 million
$8.1 million
0.75
11/16/2018
Tap to view 1 drug
Drug Indication Stage News
AB-SA01 S. aureus bacteremia Phase 2 Phase 1/2 trial planned for early 2019.
$15.09
+0.63  +4.36%
56.2 million
$847.7 million
11/16/2018
Tap to view 6 drugs
Drug Indication Stage News
APL-2 subcutaneous Complement-dependent Nephropathies (CDN) Phase 2 Phase 2 data due 2019.
APL-2 subcutaneous Auto-immune Hemolytic Anemia (AIHA) Phase 2 Phase 2 monotherapy data due at ASH December 3, 2018: 6:00 PM.
APL-2 PHAROAH Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 1b Phase 1b update due at ASH December 2, 2018: 6:00 PM.
APL-2 Geographic atrophy (GA) associated with age-related macular degeneration (AMD) Phase 3 Phase 3 enrollment has temporarily halted due to non-infectious inflammation in patients. Update due 1H December 2018.
APL-2 subcutaneous Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 3 Phase 3 trial initiation announced June 26, 2018.
APL-2 PADDOCK Paroxysmal Nocturnal Hemoglobinuria Phase 1 Phase 1 updated data due at ASH December 2, 2018 6:00 PM.
$0.29
-0.01  -3.32%
28.2 million
$8.2 million
11/16/2018
Tap to view 1 drug
$2.30
+0.24  +11.65%
37.8 million
$86.9 million
11/16/2018
Tap to view 1 drug
Drug Indication Stage News
APTO-253 Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Phase 1b Phase 1b clinical hold released June 29, 2018.
$23.39
+0.88  +3.91%
33.5 million
$783.5 million
11/16/2018
Tap to view 5 drugs
Drug Indication Stage News
NYX-458 Parkinson’s Disease Cognitive Impairment (healthy volunteers) Phase 1 Phase 1 data due 1H 2019.
NYX-2925 Fibromyalgia Phase 2 Phase 2 interim analysis 4Q 2018 with top-line data due 2H 2019.
NYX-2925 Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Phase 2 Phase 2 data due early 1Q 2019.
NYX-2925 Healthy volunteers Phase 1 Pharmacodynamic/ biomarker data due 2H 2018.
NYX-783 Post-traumatic stress disorder (PTSD) Phase 2 Phase 2 data due 2H 2019.
$2.85
+0.17  +6.34%
22.7 million
$64.7 million
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
APVO414 Castration-resistant prostate cancer Phase 1 Development terminated - noted November 14, 2018.
Otlertuzumab Relapsed or refractory peripheral T-cell lymphoma Phase 2 Development terminated - noted November 14, 2018.
APVO436 Acute myeloid leukemia (AML) Phase 1 Phase 1 dosing to commence 4Q 2018.
$16.86
+0.05  +0.30%
24.9 million
$420.2 million
11/16/2018
Tap to view 4 drugs
Drug Indication Stage News
AQST-117 Amyotrophic Lateral Sclerosis Phase 3 Top-line data due December 2018.
Sympazan Lennox-Gastaut Syndrome Approved Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Libervant - AQST-203 Epileptic seizures Phase 3 NDA filing due 2018.
AQST-119 Erectile dysfunction CRL CRL issued November 16, 2018.
$2.16
+0.03  +1.17%
23.5 million
$50.8 million
11/16/2018
Tap to view 4 drugs
Drug Indication Stage News
Rosiptor (AQX-1125) Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase 2 Phase 2 trial has been discontinued.
AQX-1125 LEADERSHIP Bladder pain syndrome/interstitial cystitis (BPS/IC) Phase 3 Phase 3 data released June 27, 2018. Primary endpoint not met.
AQX-1125 KINSHIP Atopic dermatitis (AD) Phase 2 Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 FLAGSHIP Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trail failed - July 2015
$6.01
+0.1  +1.69%
11.2 million
$67.2 million
11/16/2018
Tap to view 2 drugs
Drug Indication Stage News
VRS-317 VELOCITY Growth hormone deficiency, or GHD - pediatric Phase 3 Phase 3 top-line data released September 21, 2017 - primary endpoint not met.
AVB-S6-500 Ovarian cancer Phase 1b Phase 1b initial safety data due mid-2019.
$1.00
  +0.00%
15.2 million
$15.2 million
11/16/2018
Tap to view 2 drugs
$12.62
+0.14  +1.12%
$
11/16/2018
Tap to view 3 drugs
Drug Indication Stage News
AR-301 (Salvecin) Staphylococcus aureus Phase 3 Phase 3 trial to be initiated 4Q 2018,
AR-105 (Aerucin) Pseudomonas aeruginosa Phase 2 Phase 2 interim data due mid-2019.
AR-101 (Aerumab) Pseudomonas aeruginosa Phase 2 Phase 2/3 trial to be initiated 2H 2019.
$2.99
+0.06  +2.05%
62.1 million
$185.8 million
11/16/2018
Tap to view 4 drugs
Drug Indication Stage News
Tenapanor (T3MPO-2) Constipation-predominant irritable bowel syndrome (IBS-C) PDUFA PDUFA date September 13, 2019.
RDX7675 Hyperkalemia Phase 2 Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
Tenapanor Hyperphosphatemia in end-stage renal disease (ESRD) patients Phase 3 Phase 3 released February 15, 2017 - primary endpoint met. Data from second Phase 3 trial due 2019.
Tenapanor (T3MPO-1) Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
ARGX argenx SE
$93.23
+1.4  +1.52%
35.9 million
$3.3 billion
11/16/2018
Tap to view 5 drugs
Drug Indication Stage News
Efgartigimod (ARGX-113) Pemphigus vulgaris (PV) Phase 2 Phase 2 data due 1H 2019.
ARGX-110 Relapsed/refractory cutaneous T-cell lymphoma (CTCL) Phase 2 Phase 2 interim data ASH 2017 - of 22 patients 1 CR, 2 PRs, 10 SD. Full data due by the end of 2018.
ARGX-110 Acute myeloid leukemia (AML) Phase 1 Phase 1/2 data at ASH December 2, 2018, 6:00 PM.
ARGX-113 Immune thrombocytopenia (ITP) Phase 2 Phase 3 trial to be initiated 2H 2019. Phase 2 full data due at ASH December 3, 2018.
Efgartigimod Myasthenia gravis (MG) Phase 3 Phase 3 trial initiation announced September 5, 2018.
ARLZ
$0.00
  +0.00%
$